Skip to main content

Entrada Therapeutics, Inc.

TRDA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001689375

In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Entrada Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
7 filings
4 insiders, $5.92M in total
Insiders trading
4
Net value
−$5.92M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Entrada Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Entrada Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
MPM Bioventures 2018, L.P.10% Owner3,885,115IndirectSep 9, 20264
MPM BioVentures 2018 GP LLC10% Owner3,885,115IndirectSep 9, 20264
MPM BioVentures 2018 LLC10% Owner3,885,115IndirectSep 9, 20264
Gadicke Ansbert10% Owner3,885,115IndirectSep 9, 20264
Evnin Luke10% Owner3,885,115IndirectSep 9, 20264
Foley Todd10% Owner3,885,115IndirectSep 9, 20264
MPM BioVentures 2014, L.P.10% Owner3,885,115IndirectSep 9, 20264
MPM BioVentures 2014 (B), L.P.10% Owner3,885,115IndirectSep 9, 20264
MPM Asset Management Investors BV2014 LLC10% Owner3,885,115IndirectSep 9, 20264
MPM Bioventures 2018 (B), L.P.10% Owner3,885,115IndirectSep 9, 20264
MPM Asset Management Investors BV2018 LLC10% Owner3,885,115IndirectSep 9, 20264
MPM BioVentures 2014 LLC10% Owner3,885,115IndirectSep 9, 20264
MPM BioVentures 2014 GP LLC10% Owner3,885,115IndirectSep 9, 20264
Doshi DipalCEO517,290Sep 3, 20262
Dowden Nathan JPresident & COO196,060Sep 3, 20264
Sethuraman NatarajanPresident, Research & Develop.214,238Sep 3, 20263
Wentworth Kory JamesChief Financial Officer117,277Sep 3, 20266
Parmar KushDirector2,691,337IndirectAug 10, 20264
Rocklage Scott M10% Owner2,783,781Aug 10, 20263
Schwab Andrew J.10% Owner2,783,781Aug 10, 20263
5AM Ventures V, L.P.10% Owner2,783,781Aug 10, 20263
5AM Opportunities I, L.P.10% Owner2,783,781Aug 10, 20263
5AM Opportunities I (GP), LLC10% Owner2,783,781Aug 10, 20263
5AM Partners V, LLC10% Owner2,783,781Aug 10, 20263
Kim Peter SDirector117,412Jun 12, 20261
Thistle MaryDirector–Jun 12, 20261
Zeiher Bernhardt GDirector5,000IndirectJun 12, 20262
Chapman GinaDirector–Jun 12, 20261
Radhakrishnan MahaDirector–Jun 12, 20261
Baker Julian10% Owner4,691,392IndirectNov 24, 20252
Baker Felix10% Owner4,691,392IndirectNov 24, 20252
Baker Bros. Advisors LP10% Owner4,691,392IndirectNov 24, 20252
Baker Bros. Advisors (GP) LLC10% Owner4,691,392IndirectNov 24, 20252
Kreher NerissaChief Medical Officer40,037Sep 6, 20230
Crowley John FDirector5,000Jun 12, 20230
Nuechterlein CaroleDirector–Jun 6, 20220
Roche Holding Ltd10% Owner2,813,525IndirectNov 4, 20210
Roche Finance Ltd10% Owner2,813,525IndirectNov 4, 20210
Redmile Group, LLC10% Owner1,954,420IndirectNov 4, 20210
Green Jeremy10% Owner1,954,420IndirectNov 4, 20210
Redmile Biopharma Investments III, L.P.10% Owner1,954,420IndirectNov 4, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 22, 2023 (view filing)Jun 20-222 daysDowden Nathan JChief Operating OfficerSSale−16.0K$15.42−$246.4K−27.3%42.5K after2 lots10b5-1
Jun 23, 2023 (view filing)Jun 212 daysWentworth Kory JamesChief Financial OfficerSSale−17.5K$15.01−$262.6K−38.5%28.0K after2 lots10b5-1
Jul 12, 2023 (view filing)Jul 10-112 daysSethuraman NatarajanChief Scientific OfficerSSale−17.9K$18.03−$322.4K−10.4%153.4K after2 lots10b5-1
Jul 12, 2023 (view filing)Jul 10-112 daysDowden Nathan JChief Operating OfficerSSale−7.10K$18.03−$127.9K−16.7%35.4K after2 lots10b5-1
Jul 12, 2023 (view filing)Jul 10-112 daysWentworth Kory JamesChief Financial OfficerSSale−10.0K$17.99−$179.9K−21.4%36.7K after2 lots10b5-1
Aug 4, 2023 (view filing)Aug 2-42 daysKreher NerissaChief Medical OfficerSSale−26.7K$14.76−$394.2K−49.6%27.1K after5 lots10b5-1
Aug 16, 2023 (view filing)Aug 142 daysDoshi DipalPresident and CEOSSale−1.00K$15.67−$15.7K−0.5%201.1K after10b5-1
Sep 6, 2023 (view filing)Sep 6Same dayDowden Nathan JChief Operating OfficerSSale−972$13.47−$13.1K−2.0%48.2K after2 lots10b5-1
Sep 6, 2023 (view filing)Sep 6Same dayKreher NerissaChief Medical OfficerSSale−892$13.47−$12.0K−2.2%40.0K after2 lots10b5-1
Sep 6, 2023 (view filing)Sep 6Same dayWentworth Kory JamesChief Financial OfficerSSale−950$13.48−$12.8K−1.9%49.6K after2 lots10b5-1
Sep 15, 2023 (view filing)Sep 132 daysDoshi DipalPresident and CEOSSale−1.00K$15.00−$15.0K−0.4%248.3K after10b5-1
Oct 19, 2023 (view filing)Oct 172 daysDoshi DipalPresident and CEOSSale−1.00K$15.00−$15.0K−0.4%247.3K after10b5-1
Nov 13, 2023 (view filing)Nov 13Same dayDoshi DipalPresident and CEOSSale−1.00K$16.23−$16.2K−0.4%246.3K after10b5-1
Dec 22, 2023 (view filing)Dec 202 daysDoshi DipalPresident and CEOSSale−1.00K$15.00−$15.0K−0.4%245.3K after10b5-1
Dec 26, 2023 (view filing)Dec 21-265 daysWentworth Kory JamesChief Financial OfficerSSale−12.5K$15.59−$194.8K−20.1%49.6K after4 lots10b5-1
Jan 18, 2024 (view filing)Jan 162 daysDoshi DipalCEOSSale−1.00K$15.99−$16.0K−0.4%244.3K after10b5-1
Feb 20, 2024 (view filing)Feb 155 daysDoshi DipalCEOSSale−1.00K$15.00−$15.0K−0.4%243.3K after10b5-1
Mar 8, 2024 (view filing)Mar 62 daysDowden Nathan JPresident & COOSSale−1.83K$12.32−$22.5K−1.3%137.2K after10b5-1
Mar 8, 2024 (view filing)Mar 62 daysWentworth Kory JamesChief Financial OfficerSSale−4.09K$12.31−$50.3K−5.2%74.2K after10b5-1
Mar 21, 2024 (view filing)Mar 19-212 daysKim Peter SDirectorPPurchase+2.73K$12.81+$35.0K+5.8%49.8K after3 lots
Mar 26, 2024 (view filing)Mar 22-264 daysKim Peter SDirectorPPurchase+9.05K$13.58+$122.9K+18.2%58.8K after3 lots
Apr 1, 2024 (view filing)Mar 284 daysKim Peter SDirectorPPurchase+1.51K$13.75+$20.8K+2.6%60.3K after
Apr 10, 2024 (view filing)Apr 82 daysKim Peter SDirectorPPurchase+2.60K$13.57+$35.3K+4.3%62.9K after
May 10, 2024 (view filing)May 8-92 daysKim Peter SDirectorPPurchase+4.48K$14.14+$63.3K+7.1%67.4K after2 lots
May 20, 2024 (view filing)May 16-174 daysDoshi DipalCEOSSale−3.00K$15.04−$45.1K−0.9%337.4K after2 lots10b5-1
May 20, 2024 (view filing)May 16-204 daysSethuraman NatarajanChief Scientific OfficerSSale−19.0K$15.16−$287.7K−9.1%190.1K after3 lots10b5-1
Jun 14, 2024 (view filing)Jun 131 dayDoshi DipalCEOSSale−1.00K$16.17−$16.2K−0.3%336.4K after10b5-1
Jun 26, 2024 (view filing)4:53 PM ETJun 251 dayBaker Julian and 3 others10% OwnerPPurchase+3.37M$14.85+$50.0M–3.08M afterDerivative2 lots
Jul 10, 2024 (view filing)Jul 82 daysWentworth Kory JamesChief Financial OfficerSSale−1.76K$14.95−$26.3K−2.1%81.4K after10b5-1
Jul 16, 2024 (view filing)Jul 12-154 daysDoshi DipalCEOSSale−1.90K$17.84−$33.9K−0.6%334.5K after2 lots10b5-1
Jul 16, 2024 (view filing)Jul 12-154 daysSethuraman NatarajanChief Scientific OfficerSSale−1.24K$18.00−$22.3K−0.7%188.8K after2 lots10b5-1
Aug 20, 2024 (view filing)Aug 164 daysDowden Nathan JPresident & COOSSale−27.1K$16.27−$440.8K−17.2%130.1K after2 lots10b5-1
Sep 10, 2024 (view filing)Sep 6-94 daysSethuraman NatarajanChief Scientific OfficerSSale−3.24K$15.12−$49.0K−1.7%183.8K after2 lots10b5-1
Sep 10, 2024 (view filing)Sep 6-94 daysDowden Nathan JPresident & COOSSale−2.30K$15.09−$34.8K−1.8%126.0K after2 lots10b5-1
Sep 10, 2024 (view filing)Sep 91 dayWentworth Kory JamesChief Financial OfficerSSale−3.19K$14.97−$47.8K−4.0%76.5K after10b5-1
Sep 30, 2024 (view filing)Sep 264 daysDowden Nathan JPresident & COOSSale−847$16.00−$13.6K−0.7%125.1K after10b5-1
Oct 18, 2024 (view filing)Oct 162 daysSethuraman NatarajanPresident, Research & Develop.SSale−600$18.00−$10.8K−0.3%183.2K after10b5-1
Nov 6, 2024 (view filing)Nov 4-62 daysSethuraman NatarajanPresident, Research & Develop.SSale−18.2K$18.62−$339.3K−9.9%165.0K after4 lots10b5-1
Nov 13, 2024 (view filing)Nov 112 daysWentworth Kory JamesChief Financial OfficerSSale−8.64K$19.98−$172.6K−10.5%73.8K after10b5-1
Nov 13, 2024 (view filing)Nov 11-132 daysSethuraman NatarajanPresident, Research & Develop.SSale−4.11K$20.03−$82.3K−2.5%160.9K after2 lots10b5-1
Dec 3, 2024 (view filing)Nov 29-Dec 34 daysSethuraman NatarajanPresident, Research & Develop.SSale−15.9K$20.18−$320.6K−9.9%145.0K after3 lots10b5-1
Dec 3, 2024 (view filing)Nov 29-Dec 24 daysWentworth Kory JamesChief Financial OfficerSSale−6.00K$20.00−$120.0K−7.5%73.8K after2 lots10b5-1
Dec 12, 2024 (view filing)5:00 PM ETDec 10-112 daysGadicke Ansbert and 9 others10% OwnerSSale−44.7K$20.51−$917.1K−1.0%4.38M after2 lots
Dec 12, 2024 (view filing)5:00 PM ETDec 10-112 daysMPM Bioventures 2018, L.P. and 2 others10% OwnerSSale−44.7K$20.51−$917.1K−1.0%4.38M after2 lotsDuplicate filing
Mar 19, 2025 (view filing)Mar 172 daysWentworth Kory JamesChief Financial OfficerSSale−1.78K$10.67−$19.0K−1.6%109.5K after10b5-1
Jun 18, 2025 (view filing)May 13-14, 2024401 daysKim Peter SDirectorPPurchase+50.0K$14.64+$731.8K+74.2%117.4K afterAmended2 lots
Jul 1, 2025 (view filing)Jun 27-Jul 14 daysParmar KushDirector, 10% OwnerSSale−125.0K$6.93−$866.5K−10.2%1.10M after6 lots
Jul 1, 2025 (view filing)8:32 PM ETJun 27-Jul 14 daysRocklage Scott M and 5 others10% OwnerSSale−92.9K$6.93−$644.0K−2.8%3.18M after3 lots
Jul 1, 2025 (view filing)8:32 PM ETJun 27-Jul 14 daysRocklage Scott M and 5 others10% OwnerSSale−32.1K$6.93−$222.6K−2.8%1.10M after3 lots
Jul 11, 2025 (view filing)Jul 92 daysParmar KushDirector, 10% OwnerSSale−27.0K$7.50−$202.5K−2.4%1.09M after2 lots